MA44008A - 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b - Google Patents
1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2bInfo
- Publication number
- MA44008A MA44008A MA044008A MA44008A MA44008A MA 44008 A MA44008 A MA 44008A MA 044008 A MA044008 A MA 044008A MA 44008 A MA44008 A MA 44008A MA 44008 A MA44008 A MA 44008A
- Authority
- MA
- Morocco
- Prior art keywords
- nr2b
- substituted
- selective nmda
- nmda modulators
- triazoles used
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293680P | 2016-02-10 | 2016-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44008A true MA44008A (fr) | 2018-12-19 |
Family
ID=58054551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044008A MA44008A (fr) | 2016-02-10 | 2017-02-09 | 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10071988B2 (fr) |
| EP (1) | EP3414233A1 (fr) |
| JP (1) | JP6923543B2 (fr) |
| KR (1) | KR20180108822A (fr) |
| CN (1) | CN109071488B (fr) |
| AU (1) | AU2017217542B2 (fr) |
| BR (1) | BR112018016329A2 (fr) |
| CA (1) | CA3014314A1 (fr) |
| EA (1) | EA201891799A1 (fr) |
| IL (1) | IL261046B (fr) |
| MA (1) | MA44008A (fr) |
| MX (1) | MX2018009752A (fr) |
| SG (1) | SG11201806750WA (fr) |
| WO (1) | WO2017139428A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3180329B1 (fr) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Derives de triazole comme des inhibiteurs de recepteur nr2b |
| PT3180315T (pt) | 2014-08-15 | 2020-05-27 | Janssen Pharmaceuticals Inc | Pirazoles |
| MX2018000352A (es) | 2015-07-09 | 2018-08-15 | Janssen Pharmaceutica Nv | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| EP3774732A4 (fr) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| CA3103351A1 (fr) | 2018-07-03 | 2020-01-09 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | Agonistes inverses de pqsr |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| EP3983413A1 (fr) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazolo-pyrazines substituées et leur utilisation en tant que modulateurs du récepteur de glun2b |
| SG11202112407PA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| CN110128354A (zh) * | 2019-06-20 | 2019-08-16 | 大连大学 | 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法 |
| WO2021253180A1 (fr) * | 2020-06-15 | 2021-12-23 | Novartis Ag | Méthyl(r)-2-(fluorométhyl)-5-oxo-4-phényl-4,5,6, 7-tétrahydro-1h-cyclopenta[b]pyridine-3-carboxylate et méthyl(r)-2-(fluorométhyl)-5-oxo-4-phényl-1,4,5,7-tétrahydrofuro[3,4-b]pyridine-3-carboxylate utilisés en tant qu'activateurs de cav1.2 |
| US20260098019A1 (en) * | 2022-10-07 | 2026-04-09 | Augusta University Research Institute, Inc. | Synthesis of nsaid conjugates as anti-inflammatory agents using the molecular hybridization |
| CN115947692B (zh) * | 2022-12-28 | 2024-12-27 | 上海再启生物技术有限公司 | 一种制备2-氯-4-(甲氧基甲基)嘧啶的方法 |
| CN120957984A (zh) * | 2023-04-04 | 2025-11-14 | 江苏亚虹医药科技股份有限公司 | 泛素特异性蛋白酶1抑制剂、其制备方法及其医药用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| KR20040111445A (ko) | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌 |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| DE10315570A1 (de) * | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Triazolderivate |
| AU2005214375A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| JP5266042B2 (ja) * | 2005-04-11 | 2013-08-21 | エール ユニヴァーシティ | 統合失調症前駆症の治療方法 |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR20100017372A (ko) | 2007-05-25 | 2010-02-16 | 애보트 게엠베하 운트 콤파니 카게 | 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물 |
| WO2009028543A1 (fr) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Dérivé de pyrazole substitué |
| WO2009058261A1 (fr) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | Modulation du sommeil avec des antagonistes du récepteur nr2b |
| US20110053951A1 (en) * | 2008-03-27 | 2011-03-03 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| DK2308877T3 (da) | 2008-08-05 | 2014-04-22 | Daiichi Sankyo Co Ltd | Imidazopyridin-2-on-derivater |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| WO2010043396A1 (fr) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Dérivés d’indole et de benzomorpholine en tant que modulateurs des récepteurs métabotropiques du glutamate |
| CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| EP2579717A4 (fr) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | Modulateurs allostériques positifs de mglur2 |
| JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| WO2013130855A1 (fr) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Dérivés d'indazole |
| WO2014124651A1 (fr) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Dérivés de pyrrolidine-2-acide carboxylique utilisés en tant qu'antagonistes de iglur |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| PT3180315T (pt) | 2014-08-15 | 2020-05-27 | Janssen Pharmaceuticals Inc | Pirazoles |
| EP3180329B1 (fr) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Derives de triazole comme des inhibiteurs de recepteur nr2b |
| MX2018000352A (es) | 2015-07-09 | 2018-08-15 | Janssen Pharmaceutica Nv | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| EP3774732A4 (fr) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
-
2017
- 2017-02-09 KR KR1020187026142A patent/KR20180108822A/ko not_active Withdrawn
- 2017-02-09 WO PCT/US2017/017093 patent/WO2017139428A1/fr not_active Ceased
- 2017-02-09 CN CN201780022887.6A patent/CN109071488B/zh not_active Expired - Fee Related
- 2017-02-09 MA MA044008A patent/MA44008A/fr unknown
- 2017-02-09 SG SG11201806750WA patent/SG11201806750WA/en unknown
- 2017-02-09 AU AU2017217542A patent/AU2017217542B2/en not_active Ceased
- 2017-02-09 JP JP2018541636A patent/JP6923543B2/ja not_active Expired - Fee Related
- 2017-02-09 BR BR112018016329A patent/BR112018016329A2/pt not_active Application Discontinuation
- 2017-02-09 MX MX2018009752A patent/MX2018009752A/es unknown
- 2017-02-09 CA CA3014314A patent/CA3014314A1/fr active Pending
- 2017-02-09 EA EA201891799A patent/EA201891799A1/ru unknown
- 2017-02-09 US US15/428,710 patent/US10071988B2/en active Active
- 2017-02-09 EP EP17705768.4A patent/EP3414233A1/fr not_active Withdrawn
-
2018
- 2018-07-26 US US16/046,332 patent/US10233173B2/en active Active
- 2018-08-08 IL IL261046A patent/IL261046B/en unknown
- 2018-12-31 US US16/237,333 patent/US10766880B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170226089A1 (en) | 2017-08-10 |
| AU2017217542A1 (en) | 2018-08-23 |
| JP2019504854A (ja) | 2019-02-21 |
| EA201891799A1 (ru) | 2019-02-28 |
| US10766880B2 (en) | 2020-09-08 |
| CN109071488B (zh) | 2021-08-13 |
| KR20180108822A (ko) | 2018-10-04 |
| AU2017217542B2 (en) | 2021-06-03 |
| CA3014314A1 (fr) | 2017-08-17 |
| JP6923543B2 (ja) | 2021-08-18 |
| SG11201806750WA (en) | 2018-09-27 |
| MX2018009752A (es) | 2019-02-07 |
| IL261046A (en) | 2019-02-28 |
| CN109071488A (zh) | 2018-12-21 |
| US20180334451A1 (en) | 2018-11-22 |
| US10233173B2 (en) | 2019-03-19 |
| IL261046B (en) | 2021-09-30 |
| US20190135791A1 (en) | 2019-05-09 |
| WO2017139428A1 (fr) | 2017-08-17 |
| EP3414233A1 (fr) | 2018-12-19 |
| US10071988B2 (en) | 2018-09-11 |
| BR112018016329A2 (pt) | 2018-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1009I2 (fr) | Composés utilisés comme inhibiteurs de kinase | |
| CY1123853T1 (el) | Ρυθμιστες nrf2 | |
| IL261046B (en) | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators | |
| MA52157A (fr) | Dinucléotides cycliques de purine utilisés comme modulateurs de sting | |
| MX389001B (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| EP3353328A4 (fr) | Modulateurs de l'expression de kras | |
| JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
| MA45646A (fr) | Derives de benzimidazole comme des modulateurs de ror-gamma | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
| EP3727401A4 (fr) | Composés dinucléotidiques cycliques utilisés comme agonistes sting | |
| MA49357A (fr) | Composés, compositions et méthodes permettant de moduler le cftr | |
| MA46373A (fr) | Composés utilisés comme modulateurs de ror gamma | |
| WO2015191951A3 (fr) | Modulation d'activité du complément | |
| EP3681499A4 (fr) | Composés utilisés comme inhibiteurs de ras et leur utilisation | |
| EP3622034A4 (fr) | Composition(s) de revêtement | |
| HUE052833T2 (hu) | Eljárás 2,5-furándikarbonsav (FDCA) elõállítására | |
| EP3386952A4 (fr) | Composés de benzimidazolium, pyrido-imidazolium ou pyrazino-imidazolium substitués utilisés comme agents chimiothérapeutiques | |
| EP3552017A4 (fr) | Composés, compositions et méthodes | |
| MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
| UA117779C2 (uk) | Піразини як модулятори gpr6 | |
| AU2016361427A8 (en) | Platinum anticancer agents | |
| EA201792262A1 (ru) | Пироглутамат вортиоксетина | |
| EP3368539A4 (fr) | Composés indazole substitués utilisés en tant qu'inhibiteurs de rorgammat et utilisations associées | |
| WO2014152809A3 (fr) | Analogues de pparo et de 20-oh-pge2, et procédés d'utilisation de ceux-ci |